NCT07717567Recruiting
Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression
The Diagnostic and Prognostic Role of Plasma Biomarkers in Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy. 2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard. The study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 16 Jul 2026
- Start date
- 12 Sept 2023
- Primary completion date
- 1 Jun 2032
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Alzheimer disease
- NCT number
- NCT07717567
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 12 Sept 2023 to the primary completion date, 1 Jun 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
- Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
- Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
- Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
Other
- Pregnancy or breastfeeding.
- Subjects who require a legal guardian or tutor.
- Pregnancy.
- Subjects who are unable to give informed consent and require a legal guardian or tutor.
Who the study is looking for
- Age greater than or equal to 40 years (patients of childbearing age are admitted).
- Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.
- Mini-Mental State Examination (MMSE) score greater than or equal to 18.
- Additional inclusion criterion for the validation sub-study:
- Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Ospedale San Raffaele - Cognitive Disorders and Dementia Center (CDCD) Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.